By David Westman, Global Product Marketing Manager BioProcess
Chromatography Resins, GE Healthcare
A problem with traditional mAb manufacturing is that there are so many potential entry points for microbial contamination. There are, however, ways to shut the door on contamination.
A complex issue
Monoclonal antibody (mAb) manufacturing is complex. This leads to many potential entry points for microbial contamination. What can you do to minimize the risk to patients—and your reputation?